Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of low rates of breastfeeding on incidences of breast cancer.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving early diagnosis of cancer, including breast cancer, is a priority for the National Health Service. The public health benefits of breastfeeding for child and maternal health are significant and well established. Evidence suggests a range of potential benefits, for example, research published in the British Medical Journal found breastfeeding gave protection against breast cancer.
We want to ensure that every parent and carer understands the benefits of breastfeeding and has access to the high-quality infant feeding services they need, in their local area, to achieve their breastfeeding goals. Through the Family Hubs and Start for Life Programme, we are investing £50 million to increase the range of specialist support, which is enabling parents to access face-to-face and virtual support whenever they need it.
Asked by: Damien Moore (Conservative - Southport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress she has made on increasing access to cancer screening in the North West.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England North West has carried out significant work to improve access to cancer screening in the area, including: insight work into cervical screening, which has highlighted some issues, resulting in the piloting of potential solutions; a breast mobile site review being carried out, with findings and recommendations to be shared with trusts to act upon; five bowel and seven breast providers have been trained to use data to develop a Health Equity Audit, which will be submitted at the end of June 2024, with funding being offered to providers to design, develop, implement, and evaluate an intervention to reduce inequalities and barriers experienced by a population group they have identified in their Health Equity Audit; and funding being provided for Improving Uptake in Screening Officers, working to support non responders to take up the offer of breast screening.
Asked by: Kate Osborne (Labour - Jarrow)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that people who require enzyme replacement therapy receive that medication in a timely manner.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.
Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.
Asked by: Kate Osborne (Labour - Jarrow)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of the availability of enzyme replacement therapy.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.
Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.
Asked by: Chloe Smith (Conservative - Norwich North)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what assessment he has made of the impact of proposed changes to Personal Independence Payment on people living with (a) cancer and (b) the long-term side effects of cancer treatment.
Answered by Mims Davies - Minister of State (Department for Work and Pensions)
Modernising Support for Independent Living: The Health and Disability Green Paper looks at different options to reshape the current welfare system so that we can provide better targeted support to those who need it most. We are considering these options through our 12-week consultation which was published on Monday 29 April and will close on Monday 22 July at 11:59pm. Any possible impacts on people living with cancer and people living with the long-term side effects of cancer treatment will be considered as necessary.
There will be no immediate changes to PIP, or to health assessments. All scheduled PIP assessments and payments will proceed as normal, and claimants should continue to engage as usual and provide any necessary information or updates regarding their circumstances.
We encourage everyone to respond to the consultation which can be found here, so that we are able to hear from as many disabled people, people with health conditions, their representatives, and local stakeholders as possible on these important issues.
Asked by: Claire Hanna (Social Democratic & Labour Party - Belfast South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has given to the potential merits of increasing the level of funding for research into (a) pancreatic cancer and (b) other cancers with lower survival rates.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Government is proud to invest £1.3 billion per year on health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was over £121.8 million for 2022/23, and more is spent on cancer than any other disease group. Our investments in cancer, including rare and less survivable cancers such as pancreatic cancer, are pivotal to informing efforts to improve cancer prevention, treatment, and care.
As part of our commitment to driving more and better research into less survivable cancers, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers via the Medical Research Council’s two-day cancer sandpit strategic funding opportunity in 2023, which focused on technological innovation for understanding cancers, including pancreatic cancer, with the poorest survival rates.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer and other cancers with lower survival rates. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality, rather than against specific disease funding allocations. We would welcome more applications from researchers working on pancreatic cancer prevention, treatment, and care.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to assess the level of regional variation in the detection of lung cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Targeted Lung Health Checks have been implemented in the most deprived areas of England, where people are four times more likely to smoke and are therefore at higher risk of lung cancer. This has resulted in greater numbers of lung cancer being detected in these areas than previously. The programme will be converted to a Targeted Lung Cancer Screening Programme and fully rolled out in all regions by 2030.
Asked by: Karin Smyth (Labour - Bristol South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of progress in the development of a clinical analytical service for specialised commissioning.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
Commissioners of Specialised Services have access to the analysis of clinical data via their regional business intelligence teams, or the nationally commissioned Commissioning Support Unit (CSU) service provision.
Routine reporting can be accessed via the National Commissioning Data Repository, and more focused analytics can be performed across commissioning and clinical datasets collected by NHS England. NHS England has developed 181 Specialised Services Quality Dashboards alongside service specifications, which provide additional data to monitor the quality of services and maintain clinical registries ranging from bowel cancer to pulmonary hypertension. The full list is available at the following link:
https://digital.nhs.uk/data-and-information/clinical-audits-and-registries
Asked by: Alexander Stafford (Conservative - Rother Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an estimate of the number of hospital admissions for issues related to cigar smoking in the last (a) 12 months, (b) five years and (c) 20 years.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Smoking is responsible for approximately 80,000 deaths a year in the United Kingdom, and causes around one in four UK cancer deaths. It also costs our country £21.8 billion a year, and puts a huge burden on the National Health Service. The latest estimates from Action on Smoking and Health put the cost of smoking to the NHS at £1.9 billion a year.
All tobacco products are harmful. Tobacco smoke from cigars leads to the same types of diseases as cigarette smoke. Research has shown that using smokeless tobacco raises the risk of both mouth and oesophageal cancer. Data from the Office for Health Improvement and Disparities’ Smoking Profile showed that in 2019/20 there were an estimated 448,031 smoking attributable hospital admissions, but we cannot differentiate by the type of tobacco.
As such, the Department does not hold data on the annual costs to the NHS of cigar smoking and snuff taking, nor data on the number of hospital admissions for issues related to cigar smoking or snuff taking in the last 12 months, five years, or 20 years.
Asked by: Alexander Stafford (Conservative - Rother Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an estimate of the number of hospital admissions for issues related to the taking of snuff in the last (a) 12 months, (b) five years and (c) 20 years.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Smoking is responsible for approximately 80,000 deaths a year in the United Kingdom, and causes around one in four UK cancer deaths. It also costs our country £21.8 billion a year, and puts a huge burden on the National Health Service. The latest estimates from Action on Smoking and Health put the cost of smoking to the NHS at £1.9 billion a year.
All tobacco products are harmful. Tobacco smoke from cigars leads to the same types of diseases as cigarette smoke. Research has shown that using smokeless tobacco raises the risk of both mouth and oesophageal cancer. Data from the Office for Health Improvement and Disparities’ Smoking Profile showed that in 2019/20 there were an estimated 448,031 smoking attributable hospital admissions, but we cannot differentiate by the type of tobacco.
As such, the Department does not hold data on the annual costs to the NHS of cigar smoking and snuff taking, nor data on the number of hospital admissions for issues related to cigar smoking or snuff taking in the last 12 months, five years, or 20 years.